Spots Global Cancer Trial Database for Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
Official Title: Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Study ID: NCT05953337
Interventions
Study Description
Brief Summary: This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California - Irvine, Orange, California, United States
University of Louisville, Louisville, Kentucky, United States
Beth Israel Deaconess, Boston, Massachusetts, United States
Charlotte Radiology, Charlotte, North Carolina, United States
HCA Healthcare Research Institute (Sarah Cannon), Nashville, Tennessee, United States
University of Utah, Salt Lake City, Utah, United States
Contact Details
Name: Andrew Kennedy, MD
Affiliation: Director, Radiation Oncology Research at Sarah Cannon
Role: PRINCIPAL_INVESTIGATOR
Name: Aravind Arepally, MD
Affiliation: ABK Biomedical, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
